**Supplementary Table 1** Univariate and multivariate analysis of 30-day mortality.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | 30-day mortality | | | |
| Univariate analysis | | Multivariate analysis | |
| OR (CI) | p | OR (CI) | p |
| Age | 1.011 (0.991-1.030) | 0.285 |  |  |
| Male gender | 1.167 (0.434-1.599) | 0.584 |  |  |
| Comorbidities | | | | |
| Diabetes | 0.638 (0.295-1.379 | 0.254 |  |  |
| Chronic renal failure | 1.681 (0.758-3.728) | 0.202 |  |  |
| COPD | 2.256 (0.877-5.802) | 0.091 |  |  |
| Chronic hepatic failure | 1.365 (0.409-4.556) | 0.613 |  |  |
| Chronic heart failure | 1.394 (0.721-2.695) | 0.323 |  |  |
| Colon cancer | 2.107 (0.726-6.111) | 0.170 |  |  |
| HIV positive | 0.832 (0.091-7.615) | 0.870 |  |  |
| Previous valvulopathy | 2.210 (1.001-4.877) | 0.050 |  |  |
| IV drug user | 1.021 (0.270-3.859) | 0.976 |  |  |
| Prosthetic IE | 1.580 (0.850-2.934) | 0.148 |  |  |
| Vegetation >10 mm | 1.406 (0.678-2.918) | 0.360 |  |  |
| Isolated microorganisms | | | | |
| *Staphylococcus* spp. | 1.657 (0.827-3.321) | 0.154 |  |  |
| *Streptococcus* spp. | 0.394 (0.131-1.182) | 0.097 |  |  |
| *Enterococcus* spp. | 1.216 (0.414-3.572) | 0.722 |  |  |
| Non-HACEK Gram negative | 3.775 (1.155-12.335) | 0.028 | 6.684 (1.872-23-863) | 0.003 |
| Fungi | 3.391 (0.208-55.293) | 0.391 |  |  |
| Negative | 0.614 (0.299-1.258) | 0.182 |  |  |
| Complications | | | | |
| Heart failure | 1.253 (0.617-2.545) | 0.532 |  |  |
| Perivalvular extension | 2.136 (1.029-4.433) | 0.042 | 2.707 (1.172-6.253) | 0.020 |
| Cerebral embolism | 3.927 (1.841-8.376) | <0.001 | 4.354 (1.927-9.837) | <0.001 |
| Peripheral embolism | 2.497 (1.000-6.232) | 0.050 |  |  |
| Therapy | | | | |
| Surgery (vs. no surgery) | 0.812 (0.422-1.561) | 0.532 |  |  |
| Early surgery (vs. late) | 2.143 (0.723-6.347) | 0.169 |  |  |

CI: confidence interval; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; IE: infective endocarditis; IV: intravenous; OR: odds ratio.